vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and NETSOL TECHNOLOGIES INC (NTWK). Click either name above to swap in a different company.

NETSOL TECHNOLOGIES INC is the larger business by last-quarter revenue ($18.8M vs $13.5M, roughly 1.4× Assertio Holdings, Inc.). On growth, NETSOL TECHNOLOGIES INC posted the faster year-over-year revenue change (21.1% vs -57.9%). Over the past eight quarters, NETSOL TECHNOLOGIES INC's revenue compounded faster (10.3% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

NetSol Technologies Inc. is an American software company which makes automobile leasing software. It is based in Encino, California.

ASRT vs NTWK — Head-to-Head

Bigger by revenue
NTWK
NTWK
1.4× larger
NTWK
$18.8M
$13.5M
ASRT
Growing faster (revenue YoY)
NTWK
NTWK
+79.0% gap
NTWK
21.1%
-57.9%
ASRT
Faster 2-yr revenue CAGR
NTWK
NTWK
Annualised
NTWK
10.3%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ASRT
ASRT
NTWK
NTWK
Revenue
$13.5M
$18.8M
Net Profit
$246.8K
Gross Margin
48.0%
Operating Margin
-86.7%
6.9%
Net Margin
1.3%
Revenue YoY
-57.9%
21.1%
Net Profit YoY
121.5%
EPS (diluted)
$-4.54
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
NTWK
NTWK
Q4 25
$13.5M
$18.8M
Q3 25
$49.5M
$15.0M
Q2 25
$29.2M
$18.4M
Q1 25
$26.5M
$17.5M
Q4 24
$32.2M
$15.5M
Q3 24
$29.2M
$14.6M
Q2 24
$31.1M
$16.4M
Q1 24
$32.4M
$15.5M
Net Profit
ASRT
ASRT
NTWK
NTWK
Q4 25
$246.8K
Q3 25
$11.4M
$-2.4M
Q2 25
$-16.4M
$2.6M
Q1 25
$-13.5M
$1.4M
Q4 24
$-1.1M
Q3 24
$-2.9M
$70.8K
Q2 24
$-3.7M
$-82.9K
Q1 24
$-4.5M
$327.5K
Gross Margin
ASRT
ASRT
NTWK
NTWK
Q4 25
48.0%
Q3 25
39.4%
Q2 25
56.2%
Q1 25
49.8%
Q4 24
44.5%
Q3 24
45.0%
Q2 24
51.5%
Q1 24
48.3%
Operating Margin
ASRT
ASRT
NTWK
NTWK
Q4 25
-86.7%
6.9%
Q3 25
23.2%
-12.2%
Q2 25
-27.5%
17.4%
Q1 25
-50.0%
8.9%
Q4 24
-41.9%
-3.1%
Q3 24
-10.4%
-5.2%
Q2 24
-11.6%
4.9%
Q1 24
-13.4%
8.5%
Net Margin
ASRT
ASRT
NTWK
NTWK
Q4 25
1.3%
Q3 25
23.1%
-15.7%
Q2 25
-56.0%
14.0%
Q1 25
-51.1%
8.1%
Q4 24
-7.4%
Q3 24
-10.0%
0.5%
Q2 24
-11.8%
-0.5%
Q1 24
-13.9%
2.1%
EPS (diluted)
ASRT
ASRT
NTWK
NTWK
Q4 25
$-4.54
$0.02
Q3 25
$0.11
$-0.20
Q2 25
$-0.17
$0.22
Q1 25
$-0.14
$0.12
Q4 24
$-3.28
$-0.10
Q3 24
$-0.03
$0.01
Q2 24
$-0.04
$-0.01
Q1 24
$-0.05
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
NTWK
NTWK
Cash + ST InvestmentsLiquidity on hand
$63.4M
$18.1M
Total DebtLower is stronger
$337.0K
Stockholders' EquityBook value
$94.0M
$35.9M
Total Assets
$267.0M
$62.7M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
NTWK
NTWK
Q4 25
$63.4M
$18.1M
Q3 25
$93.4M
$22.7M
Q2 25
$98.2M
$17.4M
Q1 25
$87.3M
$18.8M
Q4 24
$100.1M
$21.3M
Q3 24
$88.6M
$24.5M
Q2 24
$88.4M
$19.1M
Q1 24
$80.7M
$12.3M
Total Debt
ASRT
ASRT
NTWK
NTWK
Q4 25
$337.0K
Q3 25
$218.2K
Q2 25
$134.6K
Q1 25
$86.8K
Q4 24
$87.0K
Q3 24
$92.6K
Q2 24
$95.8K
Q1 24
$38.6M
$130.4K
Stockholders' Equity
ASRT
ASRT
NTWK
NTWK
Q4 25
$94.0M
$35.9M
Q3 25
$105.8M
$35.8M
Q2 25
$93.3M
$37.8M
Q1 25
$108.5M
$35.5M
Q4 24
$121.1M
$33.9M
Q3 24
$130.5M
$34.7M
Q2 24
$132.2M
$34.8M
Q1 24
$134.5M
$35.3M
Total Assets
ASRT
ASRT
NTWK
NTWK
Q4 25
$267.0M
$62.7M
Q3 25
$319.8M
$62.6M
Q2 25
$273.8M
$62.4M
Q1 25
$286.4M
$58.1M
Q4 24
$284.7M
$59.1M
Q3 24
$276.0M
$62.8M
Q2 24
$279.4M
$64.2M
Q1 24
$282.0M
$63.3M
Debt / Equity
ASRT
ASRT
NTWK
NTWK
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.29×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
NTWK
NTWK
Operating Cash FlowLast quarter
$-30.0M
$-4.7M
Free Cash FlowOCF − Capex
$-5.1M
FCF MarginFCF / Revenue
-27.2%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
-19.24×
TTM Free Cash FlowTrailing 4 quarters
$-1.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
NTWK
NTWK
Q4 25
$-30.0M
$-4.7M
Q3 25
$-4.8M
$5.3M
Q2 25
$19.1M
$441.0K
Q1 25
$-12.5M
$-363.4K
Q4 24
$11.5M
$-5.1M
Q3 24
$-35.0K
$5.5M
Q2 24
$7.4M
$6.5M
Q1 24
$7.5M
$-4.2M
Free Cash Flow
ASRT
ASRT
NTWK
NTWK
Q4 25
$-5.1M
Q3 25
$4.8M
Q2 25
$-44.1K
Q1 25
$-693.0K
Q4 24
$-5.6M
Q3 24
$5.4M
Q2 24
$6.1M
Q1 24
$-4.6M
FCF Margin
ASRT
ASRT
NTWK
NTWK
Q4 25
-27.2%
Q3 25
32.1%
Q2 25
-0.2%
Q1 25
-4.0%
Q4 24
-36.1%
Q3 24
37.1%
Q2 24
37.0%
Q1 24
-29.6%
Capex Intensity
ASRT
ASRT
NTWK
NTWK
Q4 25
2.0%
Q3 25
3.2%
Q2 25
2.6%
Q1 25
1.9%
Q4 24
3.0%
Q3 24
0.0%
0.7%
Q2 24
2.6%
Q1 24
2.4%
Cash Conversion
ASRT
ASRT
NTWK
NTWK
Q4 25
-19.24×
Q3 25
-0.42×
Q2 25
0.17×
Q1 25
-0.26×
Q4 24
Q3 24
77.94×
Q2 24
Q1 24
-12.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

NTWK
NTWK

Core Revenue$18.0M96%
Other$816.8K4%

Related Comparisons